Company news
Everest Medicines Ltd. news in 2025
Everest Medicines Ltd.'s news releases, calls and decks from 2025, newest first.
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
December 17, 2025
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
December 14, 2025
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
December 11, 2025
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
November 20, 2025
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
October 30, 2025
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
October 29, 2025
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
October 16, 2025
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
October 14, 2025
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
October 12, 2025
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
October 9, 2025
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
September 14, 2025
Everest Medicines Announces Interim Results for First Half of 2025
August 28, 2025
Everest Medicines Announces Participation in September Investor Conferences
August 25, 2025
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
August 15, 2025
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
August 14, 2025
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
August 14, 2025
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
August 11, 2025
Everest Medicines Announces Full Approval of NEFECON® in Taiwan
August 6, 2025
Everest Medicines Expands Strategic Investment in I-MAB
August 1, 2025
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
July 24, 2025
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
July 4, 2025
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
July 2, 2025
Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025
June 26, 2025
Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)
June 22, 2025
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
June 20, 2025
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
June 9, 2025
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
June 6, 2025
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
May 22, 2025
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression
May 6, 2025
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
April 29, 2025
Everest Medicines Announces the "B" Marker Removal from Company's Stock Code, Effective May 2, 2025
April 27, 2025
Everest Medicines Announces Approval of "B" Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
April 21, 2025
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024
March 25, 2025
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
March 23, 2025
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
March 6, 2025
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
February 28, 2025
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
February 25, 2025
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
February 25, 2025
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
January 2, 2025
Everest Medicines Announces the Implementation of NEFECON NRDL Pricing in China
January 2, 2025